Related content

Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity

By LLerena Adriáán   Dorado Pedro   Peññas-Lledóó Eva M  

Pharmacogenomics, Vol. 10, Iss. 1, 2009-01 ,pp. : 17-28

Future Medicine

Access to resources Recommend Favorite

CYP2D6 -1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers

By LLerena Adrian   Dorado Pedro   Ramírez Ronald   Calzadilla Luis R   Peñas-LLedó Eva   Álvarez Mayra   Naranjo María EG   González Idilio   Pérez Bárbaro  

Pharmacogenomics, Vol. 14, Iss. 16, 2013-12 ,pp. : 1973-1977

Future Medicine

Access to resources Recommend Favorite

Prediction of In Vivo Drug-Drug Interactions from In Vitro Data: Factors Affecting Prototypic Drug-Drug Interactions Involving CYP2C9, CYP2D6 and CYP3A4

By Brown Hayley S.   Galetin Aleksandra   Hallifax David   Houston J. Brian  

Clinical Pharmacokinetics, Vol. 45, Iss. 10, 2006-01 ,pp. : 1035-1050

Adis International

Access to resources Recommend Favorite

CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population

By Scott Stuart A   Edelmann Lisa   Kornreich Ruth   Erazo Monica   Desnick Robert J  

Pharmacogenomics, Vol. 8, Iss. 7, 2007-07 ,pp. : 721-730

Future Medicine

Access to resources Recommend Favorite

Influence of CYP2C9 and CYP2D6 Polymorphisms on the Pharmacokinetics of Nateglinide in Genotyped Healthy Volunteers

By Kirchheiner J.  

Clinical Pharmacokinetics, Vol. 43, Iss. 4, 2004-01 ,pp. : 267-278

Adis International

Access to resources Recommend Favorite